<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004115</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067341</org_study_id>
    <secondary_id>UCLA-9712040</secondary_id>
    <secondary_id>ANTISOMA-SMART22</secondary_id>
    <secondary_id>NCI-G99-1604</secondary_id>
    <nct_id>NCT00004115</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy</brief_title>
  <official_title>Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells. It is not yet known whether&#xD;
      monoclonal antibody therapy is more effective than observation for ovarian cancer or primary&#xD;
      peritoneal cancer that is in remission.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of monoclonal antibody&#xD;
      therapy with that of observation in treating patients who have ovarian cancer or primary&#xD;
      peritoneal cancer in remission following surgery and chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of yttrium Y 90 monoclonal antibody HMFG1, in terms of survival,&#xD;
           in patients with ovarian epithelial carcinoma in remission after debulking surgery and&#xD;
           platinum-based chemotherapy.&#xD;
&#xD;
        -  Determine the toxicity and tolerability of this treatment regimen in these patients.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Evaluate this treatment regimen, in terms of the time to relapse, ECOG performance&#xD;
           status, frequency of hospitalization, changes in concurrent medication, and incidence&#xD;
           and severity of adverse events, in this patient population.&#xD;
&#xD;
      OUTLINE: This is a randomized, parallel, multicenter study. Patients are randomized to one of&#xD;
      two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive standard therapy (observation).&#xD;
&#xD;
        -  Arm II: After imaging studies of the peritoneal cavity to verify adequate fluid&#xD;
           distribution, patients receive yttrium Y 90 monoclonal antibody HMFG1 intraperitoneally&#xD;
           over 1 minute.&#xD;
&#xD;
      Quality of life is assessed in all patients prior to randomization, at weeks 4 and 8, at 3&#xD;
      months, and then every 3 months thereafter.&#xD;
&#xD;
      Patients in arm I are followed at weeks 1, 4, and 8. Patients in arm II are followed weekly&#xD;
      for 6 weeks and at weeks 8 and 12. All patients are followed every 3 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 420 patients (210 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 1998</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 monoclonal antibody HMFG1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven stage IC, II, III, or IV ovarian epithelial carcinoma or primary&#xD;
             peritoneal serous carcinoma&#xD;
&#xD;
          -  Prior complete response to 1 platinum-based chemotherapy regimen consisting of at&#xD;
             least 5 courses&#xD;
&#xD;
               -  Absence of disease on physical and radiological exam (CT scan/MRI)&#xD;
&#xD;
               -  CA 125 normal&#xD;
&#xD;
               -  No visible evidence of malignant disease on second-look laparoscopy&#xD;
&#xD;
          -  No disease relapse even if complete response to a second course of chemotherapy&#xD;
&#xD;
          -  Prior bilateral oophorectomy with or without salpingectomy, omentectomy, and total or&#xD;
             partial abdominal hysterectomy required&#xD;
&#xD;
          -  No known metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT/SGPT no greater than 2 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy except basal cell skin cancer&#xD;
&#xD;
          -  No serious physical or psychiatric disease that would preclude study entry&#xD;
&#xD;
          -  No significant loculation that would preclude good distribution of study medication&#xD;
&#xD;
          -  Human antimouse antibody negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior murine antibody&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 4-8 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent participation in other trials involving adjuvant cancer treatment&#xD;
&#xD;
          -  No other concurrent experimental therapies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan S. Berek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antisoma</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W5 3QR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

